-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 7, 2021, Corning Jereh Biopharmaceuticals announced that it will announce the PD-L1/CTLA-4 bispecific antibody KN046 combined with platinum chemotherapy at the 2021 American Society of Clinical Oncology (ASCO 2021) annual meeting in the form of a poster Phase II clinical study data of patients with advanced non-small cell lung cancer (study number: KN046-202)
KN046 combined with platinum-based chemotherapy showed good tolerability and effectiveness in first-line advanced non-small cell lung cancer; the 12-month and 15-month survival rate (OS rate) were 74.
KN046-202 (NCT04054531) is a phase II, open, multi-center clinical study designed to evaluate the efficacy, safety and tolerability of KN046 combined with platinum-based chemotherapy in patients with advanced non-small cell lung cancer.
As of January 19, 2021, a total of 87 patients with advanced non-small cell lung cancer who have not received systemic treatment were enrolled, including 51 patients with non-squamous cell carcinoma and 36 patients with squamous cell carcinoma
Among 81 patients with evaluable efficacy, the objective response rate (ORR) was 50.
The median progression-free survival (mPFS) is 5.
In terms of safety, 22 patients (25.
Note: The original text has been deleted